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Energy expenditureThe orexins are neuropeptides with critical functions in the central nervous system. These neuropeptides have
important roles in energy balance and obesity, and therefore on the accumulation of adipose tissue. Rodents
lacking orexins, typically through genetic knockouts, experience increased weight gain and accumulation of
adipose tissue. Evidence indicates that the lack of the orexins increase adiposity as a result of decreased energy
expenditure, principally through a reduction of physical activity. Different lines of evidence suggest that other
mechanisms are likely also in play, and neural inﬂuences on both white and brown adipose tissues remain to
be fully and functionally deﬁned. In addition, the orexin peptides and their receptors are expressed in adipose
tissue, with little available information as to their signiﬁcance. This review summarizes our current under-
standing of how the orexin peptides affect adipose tissue. We provide a brief introduction to the physiology
of orexins and their effects on white and brown adipose tissues in the context of energy balance. We conclude
this review by integrating this information in the context of the known physiology of the orexins. This article is
part of a Special Issue entitled: Modulation of Adipose Tissue in Health and Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The orexins or hypocretins are two neuropeptides with a wide
range of functions in the central nervous system, including control
of reward, arousal, physical activity, sleep/wake state and integration
of metabolic information [1–5]. Two independent groups ﬁrst
reported these neuropeptides in 1998, being named as either orexins
[6] or hypocretins [7]. Although both names are used synonymously
in the literature, the name orexin focuses on the ability to increase
feeding [6] while hypocretin is based on the speciﬁc hypothalamic
location of the peptide and its amino acid sequence similarity to the
incretin peptides [7]. Throughout this review we will use the term
orexin(s) to refer to the orexin/hypocretin neuropeptides.
The orexins have important roles in energy balance and obesity
[4,5,8–13]. Evidence from genetic models suggests that orexins promote
energy expenditure [14–16]. In this review we focus on how the orexinsion of Adipose Tissue in Health
icine and Innovative Sciences,
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l rights reserved.affect adipose tissue and their effects on energy expenditure and fat stor-
age. Additional aspects of the interaction between the central nervous
system and adipose tissue can be found in other reviews [17–19]. In the
next section, we provide a brief introduction to the physiology of orexins
and then focus on their effects onwhite and brown adipose tissues in the
context of energy balance.We conclude this reviewby integrating this in-
formation in the context of our knowledge of physiology of the orexins.2. The orexin neuropeptides
The orexin peptides are involved in the control of energy expendi-
ture, reward, arousal, food intake and control of sleep/wake patterns
[1–5,8,13]. In the brain, the orexin peptides are produced by neurons
located in the lateral, perifornical and dorsomedial hypothalamus
[6,7,20]. There are two orexin peptides (orexin-A and orexin-B)
[6,7] with 46% sequence identity, which are coded by a single gene,
prepro-orexin [6]. The biological effects of orexin peptides are mediat-
ed by two transmembrane, G-protein coupled receptors (orexin re-
ceptor 1, OX1R and orexin receptor 2, OX2R) [6,7]. Orexin-A has
equal afﬁnity for both orexin receptors, while orexin-B has ﬁve-fold
higher afﬁnity for OX2R than OX1R [6,21]. The intracellular signaling
mechanisms used by the orexin receptors appear to be cell speciﬁc
and involve multiple G-proteins and cellular effectors [13].
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different subtypes of orexin neurons have been identiﬁed [22], but
functional signiﬁcance of the subtypes is not yet clear. Activity of
orexin neurons is modulated by multiple metabolic indicators (i.e.,
glucose, leptin, amino acids) [23–27] as well as through intra and
extra-hypothalamic synaptic inputs [28–30]. This integration of infor-
mation at the orexin neurons, coupled with their multiple efferents to
different brain sites [31,32] supports the concept that the orexin neu-
rons act as integrators of metabolic signals to coordinate behavioral
responses [1].
Centrally, the orexin neuropeptides are well-established contribu-
tors to energy expenditure [5,13,33]. For example, mice deﬁcient in
orexin neurons developed spontaneous obesity associated with low
levels of physical activity [14] andmice overexpressing orexins are obe-
sity resistant [16]. In rats, resistance to obesity has been associatedwith
higher expression of prepro-orexin and higher behavioral sensitivity to
orexin-A injections [15,34]. Yet, it appears that multiple mechanisms
mediate the effects of the orexins in energy balance. Ventricular and
site-speciﬁc brain injection studies showed that the orexin peptides
could increase locomotor activity, food intake, sympathetic activity
and energy expenditure [6,35–38]. Consistent with this idea, repeated
injections of orexin-A in the rostral lateral hypothalamus can prevent
early obesity caused byhigh fat diet consumption, but the increase in lo-
comotor activity only accounts for a fraction of the energy expenditure
necessary to counteract the excess in caloric intake [39]. These data
highlight that orexins recruit multiple, but incompletely deﬁned mech-
anisms to control energy expenditure.
Studies in humans have mainly focused on how the orexins control
sleep/wake behavior and effectiveness of drugs targeted to orexin path-
ways to treat narcolepsy and other sleep related disorders [40–46]. The
few studies regarding the role of orexins in energy balance in humans
support the overall conclusion from animal studies, which is that the
orexins promote physical activity and energy expenditure. In humans,
as in animals, absence of orexin is correlated with narcolepsy–cataplexy
[44,46]. There is a negative association between cerebrospinal ﬂuids
orexin levels and BMI [47], and increased plasma levels of orexin in an-
orexia nervosa [48]. Overall, the human evidence is limited, but it ﬁts
with the conceptual outcome of animal studies regarding the role of
orexin function in energy balance.
3. Orexins in adipose tissue
It has been recognized for some time that the orexin peptides and
their receptors are expressed in a number of peripheral tissues, includ-
ing adipose tissue [49,50]. Even so, there are limited studies focused on
the function of orexins on adipose tissue. Digby et al. [51] were the ﬁrst
to report expression of both orexin receptors in adipose tissue obtained
from human biopsies, using both gene expression studies as well as de-
tection of receptor proteins. In addition, Digby et al. [51] found that, in
human adipocyte explants, the orexins increased PPAR-gamma 2 ex-
pression and reduced glycerol release. These results were interpreted
to suggest a positive role of the orexins in adipogenesis.
Supporting ﬁndings were recently reported by Skrzypski et al.
[52]. In cultured rodent adipose cells orexin-A increased glucose up-
take, reduced lipolysis and increased lipogenesis. These changes led
to accumulation of triacylglycerols, but the accumulation of fat
could be blocked by mechanisms interfering with PPAR-gamma.
Skrzypski et al. [52] also found that, in isolated rat adipocytes, orexin
induced adiponectin appeared to be a PPAR-gamma regulated mech-
anism. Overall, these ﬁndings raise the possibility that peripheral
orexin might promote adipose accumulation while reducing lipolysis.
These adipose tissue studies are, however, not consistent with the
overall effect of central orexin, which is to increase energy expenditure
and reduce adiposity. It would be informative to determine if in vivo
orexin effects on white adipose tissue metabolism replicate the effects
observed in isolated adipocytes. It is possible that the reported effectsare caused by peripheral release of orexin [49,50]. Nonetheless, it
seems likely that these direct orexin effects on adipose tissue are over-
ridden by the stronger central inﬂuences as discussed above and in the
central nervous system regulation studies reviewed below.4. Central orexin and white adipose tissue
Following the pioneering work of the Bartness laboratory [18,53],
the neural connections between the brain and adipose tissue have
begun to be deﬁned. Stanley et al. [54] used the pseudorabies virus
to track a polysynaptic neural pathway from mouse epididymal
white fat into the central regulatory network. Key components of
this central network included the paraventricular nucleus of the hy-
pothalamus (PVN), the lateral hypothalamus (LH), the arcuate nucle-
us of hypothalamus, and the nucleus of the solitary tract in the
brainstem. Order of infection by the tracing virus indicated that the
LH neurons project to PVN, from which their projection then leads
to adipose tissue (Fig. 1). Among the neuronal populations identiﬁed
in the LH were orexin neurons, thus linking orexin action to adipose
tissue function. These data are supported by the work from van den
Pol et al. showing orexin innervation of spinal cord sympathetic ner-
vous system efferents [55].
Adler et al. [56] recently used pseudorabies and Bartha viruses to
separately track the sympathetic efferent pathways from rat retroper-
itoneal and subcutaneous adipose tissues into the central nervous
system. Among the neurons identiﬁed in this tracking study were lat-
eral hypothalamic cells expressing orexin. It is of note here that there
was greater density of connection between orexin neurons and sub-
cutaneous fat compared to retroperitoneal fat in female rats. The
functional implications of this difference are presently speculative,
but underscore the idea that different adipose tissue sites may be in-
dependently regulated across sexes.
The orexin neurons are only one of many neuronal types with poly-
synaptic connections to white adipose tissue (WAT). Asmentioned ear-
lier, these include the arcuate nucleus of the hypothalamus, the locus
coeruleus, nucleus of the solitary tract and suprachiasmatic nucleus
[54,56]. In light of this, it is interesting to consider that the orexin neu-
rons have a wide projection pattern within the central nervous system,
which includes several of the brain sites identiﬁed in WAT retrograde
tracing studies [31]. Therefore, it is possible that the orexin neurons in-
ﬂuence WAT metabolism, not only through its projections to PVN, but
also through modulation of other brain regions. Thus, it is reasonable
to suggest that effects of orexin on WAT do not follow an exclusive
pathway, but are distributed over multiple brain sites. Finally, as the
orexin neurons appear to integrate multiple sources of metabolic and
neuronal information [57,58], it is possible that another role of these
neurons is to coordinate the response from WAT based on the brain's
perception of metabolic status.
The overall pattern of the central network innervating WAT indi-
cates sympathetic regulation of that tissue, in which orexin plays an im-
portant role. Functional studies on this point are very limited, but
intraventricular injections of orexin-A at 10 μg increase, while injec-
tions at a 10 ng dose decrease white adipose tissue SNS activity and li-
polysis [59]. The biphasic effect of orexin-A injection appears to involve
histaminergic, sympathetic and parasympathetic activity. This result
highlights two interesting points. First, orexin neurons can directly ex-
cite histaminergic neurons in the tuberomammillary nucleus [60–63]
and central histamine injections can promote WAT lipolysis [64]. This
may be another pathway by which the orexin neurons can modulate
WAT lipolysis. Second, while it is well established that WAT receives
sympathetic innervation, whether WAT receives parasympathetic in-
nervation still appears to be controversial [65–69]. If we accept that
the higher dose in the above-referenced study is more likely to affect
relevant brain sites, then the implication is that orexin increases sympa-
thetic drive to white adipose tissue, thus increasing lipolysis.
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Fig. 1. A proposed model for action of central orexin on adipose tissue. A model for peripheral orexin action is included, although the overall contribution to fat mass accumulation is
unclear. Orexin containing neurons in speciﬁc hypothalamic regions project to multiple forebrain and hindbrain sites, and with some direct projections to the RPA, which impact the
pre-SNS neurons in the IML, which then project to and impact SNS activity in BAT, presumably through UCP action, with the ultimate effect of increased energy expenditure. White fat
tissue is also affected, although the available studies contain some conﬂicts. Based on studies of orexin injected into the ventricles, the orexins would act to reduce fat storage by actions
on the sympathetic nervous system and lipoprotein lipase. It is very possible that the opposite effects could occur under different environmental conditions eliciting diverse interoceptive
cues. Abbreviations: BAT: brown adipose tissue; DMH: dorsomedial hypothalamus; EE: energy expenditure; IML: intermediolateral nucleus: LH: lateral hypothalamus; OXR1/2: orexin
receptors 1 and 2; PFH: perifornical hypothalamus: PVN: hypothalamic paraventricular nucleus; RPA: raphe pallidus; SNS: sympathetic nervous system: UCP: uncoupling protein;
WAT: white adipose tissue.
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In addition to increasing energy expenditure through locomotor activ-
ity, the orexin peptides can increase energy expenditure by modulating
brown adipose tissue thermogenesis [70]. Energy expenditure through
brown adipose tissue is controlled by the activity of the uncoupling pro-
teins (UCP) 1, 2 and 3 [70]. In brown adipose tissue, UCP uncouples ATP
production frommitochondrial respiration, resulting in dissipation of en-
ergy as heat [71,72]. Higher activity of UCP proteins results in lower efﬁ-
ciency of energy metabolism (i.e. conversion of ingested calories in body
mass) and resistance to body weight gain. However, mice deﬁcient for
UCP1, UCP2 or UCP3 do not show increased propensity for obesity
[73–76]. This might represent a case of compensatory mechanisms, in
which the lack of a function during development is balanced by increases
in other functions to maintain the overall output of the system constant.
Interestingly, over-expression of UCP3 in mice causes resistance against
obesity [77]. These data suggest that manipulation of UCP activity might
be a valid approach for therapeutic alternatives against obesity.
A recent study by Sellayah et al. demonstrated that orexin is required
for normal development of brown adipose tissue, and that orexin
knockout mice gain more weight on a high-fat diet compared to wild
typemice [78]. This is an important ﬁnding to theﬁeld of energy balance
as lack of brown adipose tissue development could hamper the ability to
defend against weight gain. In vitro studies suggested that the orexin
effect is directly on differentiation of new brown adipocytes [78], but
orexin receptor expression in these mesenchymal stem cells and
brown adipose tissue has not been fully evaluated.
Similar to the experience in white adipose tissue, viral tracing stud-
ies have identiﬁed the critical central regulatory elements for brown ad-
ipose tissue [79]. Many of the same brain locations for white adipose
tissue are also involved in brown adipose regulation [80–83], including
the PVN, LH, nucleus of the solitary tract and speciﬁcally in the case of
brown adipose tissue, the raphe pallidus. A recent study by Tupone et
al. [81] identiﬁed an important role for central orexin regardingbrown adipose tissue regulation via the sympathetic nervous system.
There is a direct orexigenic projection from LH to raphe pallidus [84]
that activates its efferents to premotor sympathetic neurons in the spi-
nal intermediolateral nucleus. Stimulation of neurons in the LH by di-
rect microinjection of NMDA produced long-lasting sympathetic and
brown adipose tissue stimulation. Injection of orexin-A in the dorsal
raphe and parapyramidal area increased brown fat adipose tissue ther-
mogenic activity and CO2 release in anesthetized rats [81]. Thus, the
orexins can increase sympathetic outﬂow to brown adipose tissue,
which thereby can increase brown adipose tissue thermogenic activity.
6. Integration of orexin effects in adipose tissue
The ability to modulate energy intake and expenditure according
to environmental conditions is key to guarantee the survival of an or-
ganism. Therefore, it is no surprise that mammals and other species
have evolved highly complex mechanisms to control energy balance.
Multiple neuropeptides can modulate energy balance through differ-
ent mechanisms, including control of food intake, thermogenic activ-
ity, sympathetic modulation, control of voluntary and spontaneous
physical activity [85]. As discussed in this review, the orexin neuro-
peptides are part of this network and can affect energy balance
through modulation of energy expenditure and intake.
Although themechanisms bywhich the orexins can promote energy
expenditure are not clear, the evidence reviewed here suggests that, in
addition to increasing physical activity [33,35], the orexins can promote
lipolysis in white adipose tissue and thermogenesis in brown adipose
tissue, both being consistent with a net effect of orexins to increase
energy expenditure. As shown by tracing studies, multiple neuronal
groups are part of the network that controls sympathetic output to
white and brown adipose tissue, including intra and extra hypothalamic
brain sites [54,56,79]. Additionally, orexin neurons have efferents to a
number of these brain sites [31]. Thus, it is likely that orexin action on
WAT metabolism is distributed over multiple brain sites. Current
Table 1
Neuropeptide effects in speciﬁc brain sites on feeding and gene expression of uncoupling
protein 1 (UCP1) in brown adipose tissue. Studies were done by preparing male Sprague
Dawley rats with cannulae aimed at speciﬁc sites, and giving speciﬁc site injections
(≤0.5 μl volume) every 2 h for 6 h during daytime hours, controlling for food intake dif-
ferences by either allowing no food or by yoking intake of a control group to that of the
treatment group. Rats were sacriﬁced 2 h after a ﬁnal set of injections. Tissue was
processed for UCP mRNA by the slot-blot method after conﬁrming probe speciﬁcity by
northern blot. AGRP: agouti-related protein; alpha-MSH: alpha-melanocyte stimulating
hormone; CART: cocaine and amphetamine related transcript; NPY: neuropeptide Y;
PVN: hypothalamic paraventricular nucleus: UCN: urocortin.
Neuropeptide system Brain site Feeding effect BAT UCP1
NPY PVN ↑ ↓
UCN PVN ↓ ↑
CART PVN ↓ ↑
α-MSH PVN ↓ ↑
AGRP DMH ↑ ↓
Orexin A LH ↑ No change
Leptin ICV ↓ ↑
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inﬂuence with regard to orexin effects on adipose tissue physiology.
In addition to the orexins, several other neuropeptides can also
modulate brown adipose tissue thermogenic activity via changes in
uncoupling protein expression (Table 1). Most of the cited work refers
to the action of these neuropeptides through different hypothalamic
sites, including the PVN. PVN is involved in the regulation of energy ex-
penditure through brown adipose tissue [86], is a major source of auto-
nomic outﬂow [87] and stimuli that inﬂuence feeding within this area
often result in changes in sympathetic nerve ﬁring rate to brown adi-
pose tissue [86]. This illustrates the notion that multiple neuropeptides
can act in concert to modulate energy expenditure.
A ﬁnal point of interest is that the orexin neurons can also modulate
food intake. If this effect is taken at face value, that implies the potential
for a divergent action of the orexin neurons in control of energy metab-
olism. It is quite plausible that different groups of orexin neurons are in-
volved in energy expenditure through separate mechanisms (including
physical activity and control of brown and white adipose tissue metab-
olism) and modulation of food intake. Another possibility is that meta-
bolic context controls the net output of the orexin neurons. The orexin
neurons are sensitive to multiple metabolic indicators and synaptic
input [23–26,29,30,88,89], suggesting that overall energy status can
drive the main output of the orexin neurons, independent of the effects
observed in particular experimental situations. In a situation of negative
energy balance, the orexin neurons could increase arousal, physical ac-
tivity and food intake drive [90–92]. In a situation of positive energy bal-
ance, the orexin neurons may favor the behavioral output of increasing
energy expenditure through multiple mechanisms.
7. Conclusions
The above literature on orexin action to inﬂuence adipose tissue illus-
trates that while much information has been gained over the last
10–15 years, there is still muchmore to know.What is currently evident
is that orexin can act both centrally andperipherally to inﬂuence lipolysis
inwhite fat and thermogenesis in brown fat, with a net effect to promote
negative energy balance and reduce adiposity (Fig. 1). Additional efforts
to understand the neural circuitry involved in orexin control of adipose
tissue will help provide therapeutic targets for obesity intervention.
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